NasdaqCM - Nasdaq Real Time Price USD

Organovo Holdings, Inc. (ONVO)

Compare

0.3402

-0.0050

(-1.45%)

At close: December 24 at 12:58:09 PM EST

0.3301

-0.01

(-2.97%)

After hours: December 24 at 4:46:39 PM EST

Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces that its oral presentation of its lead clinical stage drug FXR314 by Dr. Eric Lawitz of the Texas Liver Institute and the University of Texas Health San Antonio was featured at The Liver Meeting, sponsored by the American Association for the Stud

GlobeNewswire last month

ONVO
-1.45%
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases

SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces that its lead clinical stage drug, FXR314 will be featured in an oral presentation at The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases (AASLD). The presentation, by Dr. Eric Lawitz of the Texas Liver Instit

GlobeNewswire last month

ONVO
-1.45%
ONVO Releases Encouraging Quarterly Results

By Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo Holdings (NASDAQ:ONVO) is a biotechnology company that is both a developer of 3D tissue technology that has the potential to change the way treatments are discovered and tested, as well as being a creator of new therapies using that technology. The company released its fiscal second quarter results, which showed the

Zacks Small Cap Research last month

ONVO
-1.45%
Organovo: Fiscal Q2 Earnings Snapshot

SAN DIEGO (AP) — Organovo Holdings Inc. ONVO) on Friday reported a loss of $2.5 million in its fiscal second quarter. The San Diego-based company said it had a loss of 14 cents per share.

Associated Press Finance last month

ONVO
-1.45%
ONVO Announces Earnings and Notes Potential for Acquisition

By Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo Holdings (NASDAQ:ONVO) is a biotechnology company that is both a developer of 3D tissue technology that has the potential to change the way treatments are discovered and tested, as well as being a creator of new therapies using that technology. The company released its first quarter results, which showed the company

Zacks Small Cap Research 4 months ago

ONVO
-1.45%
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis

SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that Executive Chairman Keith Murphy presented on the company’s near and long-term outlook, operational plans, at the Jones Trading Healthcare Conference in Encinitas, CA. The webcast was recorded and can be viewed at https://wsw.com/webcast/jone

GlobeNewswire 5 months ago

ONVO
-1.45%
ONVO Increases Cash and Improves Prospects

By Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo Holdings (NASDAQ:ONVO) is a biotechnology company that is both a developer of 3D tissue technology that has the potential to change the way treatments are discovered and tested, as well as being a creator of new therapies using that technology. The company released its annual report for 2023, fiscal year ended March 31,

Zacks Small Cap Research 6 months ago

ONVO
-1.45%
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease

SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces data from a poster presented at Digestive Disease Week (DDW2024) demonstrating the potential of the Company’s lead clinical-stage compound, FXR314, in combination with tofacitinib for treating inflammatory bowel disease (IBD) using 3D models and p

GlobeNewswire 7 months ago

ONVO
-1.45%
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)

Renowned gastrointestinal diseases conference to held in Washington, D.C. May 18-21, 2024SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces it will be presenting data on the Company’s lead clinical-stage drug, FXR314 during DDW2024, which is being held in Washington, D.C. May 18-21, 2024. The post

GlobeNewswire 7 months ago

ONVO
-1.45%
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in three-dimensional (3D) human tissues, today announced the pricing of a public offering consisting of 6,562,500 shares of common stock (or pre-funded warrants in lieu thereof) and common warrants to purchase up to an aggregate of 6,562,500 shares of its

GlobeNewswire 7 months ago

ONVO
-1.45%
ONVO Announces Very Positive Phase 2 Results

By Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo Holdings (NASDAQ:ONVO) is a biotechnology company that is both a developer of 3D tissue technology that has the potential to change the way treatments are discovered and tested, as well as being a creator of new therapies using that technology. The company recently released Phase 2 results for one of the therapies being

Zacks Small Cap Research 7 months ago

ONVO
-1.45%
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in three-dimensional (3D) human tissues, today released the complete details of its 16-week, randomized, placebo-controlled, multi-center Phase 2 study of the non-steroidal, non-bile acid FXR agonist FXR314 for the treatment of metabolic function-associated steatohepatitis (MASH). St

GlobeNewswire 8 months ago

ONVO
-1.45%
Top 15 3D Printing Companies in the US

In this article, we will take a look at the top 15 3D printing companies in the US. If you want to skip our detailed analysis, you can go directly to Top 5 3D Printing Companies in the US. Recent Trends in 3D Printing According to a report by Grand View Research, the global 3D […]

Insider Monkey 8 months ago

GE

HPQ

ONVO
-1.45%
Organovo Holdings Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Organovo Holdings ( NASDAQ:ONVO ) Third Quarter 2024 Results Key Financial Results Net loss: US$3.60m (loss widened by...

Simply Wall St. 10 months ago

ONVO
-1.45%
ONVO Continues Progress

By Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo (NASDAQ:ONVO) reported its fiscal 3Q earnings and results were roughly inline with our expectations and illustrate to us that the company continues to progress toward bringing important products to market. Specifically, the company reported: • Earnings of -$0.40 per share, inline with estimates as expenses remained

Zacks Small Cap Research 10 months ago

ONVO
-1.45%
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress

SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis, based on demonstration of clinical promise in three-dimensional (3D) human tissues, today announced the presentation of preclinical data related to the company’s FXR314 development program in its proprietary 3D human tissue models of Crohn’s disease and ulcerative colitis at the

GlobeNewswire 10 months ago

ONVO
-1.45%
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress

SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as strong preclinical data, today announced that its data on the activity of FXR314 in its proprietary 3D human tissue models of Crohn’s disease and ulcerative colitis will be

GlobeNewswire 11 months ago

ONVO
-1.45%

Performance Overview

Return	ONVO	S&P 500
YTD	-69.35%	+26.63%
1-Year	-69.07%	+27.03%
3-Year	-91.54%	+27.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Organovo Holdings, Inc. (ONVO)

Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases

ONVO Releases Encouraging Quarterly Results

Organovo: Fiscal Q2 Earnings Snapshot

ONVO Announces Earnings and Notes Potential for Acquisition

Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis

ONVO Increases Cash and Improves Prospects

Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease

Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)

Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering

ONVO Announces Very Positive Phase 2 Results

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

Top 15 3D Printing Companies in the US

Organovo Holdings Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

ONVO Continues Progress

Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress

Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress

Performance Overview